A experimental medicine that lowers a blood particle linked to heart attacks and strokes did not protect volunteers in a closely watched study, and the disappointment is real. Researchers reported the result Saturday. Steven Nissen, a cardiologist at the Cleveland Clinic who led the study, said he was shocked and had high hopes for success. He was right to have them. Cardiovascular disease remains the leading cause of death in developed countries, and the report notes it kills more than 900,000 Americans each year.

The trial's logic was sound. The drug, pelacarsen, cut levels of lipoprotein(a), or Lp(a), by about 78 percent. Many adults with elevated Lp(a) do everything right, keeping cholesterol and blood pressure low, eating well, and exercising, yet still suffer heart attacks and strokes. Doctors needed a new tool for those patients. The study enrolled 8,350 adults who already had heart disease and followed them for five years. After that, the lower Lp(a) numbers did not translate into fewer cardiovascular complications.

Novartis, which sponsored the study, announced last month that the results had not met its goals but did not release specifics. That delay was a poor way to treat patients, investors and the public who were watching closely. When a trial of this size and importance misses, the sponsor should publish the full data quickly, as Nissen did through the New England Journal of Medicine and NEJM Evidence. Scientists cannot learn from a failure that remains hidden.

Researchers have offered several explanations, and none should be dismissed. Lp(a) may be a marker for another risk rather than a direct cause. Treatment may need to start earlier or last longer, or the drug may help only people with higher levels or poorer control of other risk factors. Other Lp(a)-lowering drugs from Amgen and Eli Lilly are still in testing, with results expected over the next few years. The honest conclusion is that the question is open, not closed. Patients and doctors should wait for those answers rather than abandon the idea.